Prasad Raju 4

4 · CRISPR Therapeutics AG · Filed Mar 24, 2026

AI-generated summary of this filing

Updated Mar 24, 2026

CRISPR (CRSP) CFO Prasad Raju Sells 3,708 Shares, Receives Awards

What Happened

Prasad Raju, Chief Financial Officer of CRISPR Therapeutics (CRSP), reported an open‑market sale of 3,708 common shares on March 23, 2026 at $46.78 per share, generating $173,460. The filing also shows awards and derivative activity on March 20, 2026: an option grant for 38,499 shares, an RSU grant for 27,500 shares, and a reported exercise/conversion of 6,250 derivative shares (the filing shows both acquisition and disposition of the 6,250 shares on March 20). The 3,708‑share sale was reported as required to satisfy tax withholding in connection with RSU vesting (company policy), not a discretionary trade.

Key Details

Sale: 3,708 shares sold on 2026-03-23 at $46.78; total proceeds $173,460.
Grants on 2026-03-20:
- Option/award: 38,499 shares (footnote F4) — vests 100% in 48 equal monthly installments starting April 20, 2026.
- RSU award: 27,500 shares (footnote F5) — vests quarterly from Mar 20, 2027 through Mar 20, 2030.
Prior RSU (25,000) from Mar 20, 2024 (footnote F6) had a vesting tranche on Mar 20, 2026; the sale to cover taxes (footnote F3) relates to RSU withholding.
Exercise/Conversion: 6,250 derivative shares reported acquired and disposed on 2026-03-20 (no price reported); filing shows conversion/exercise activity but does not state sale price.
Lock‑up: Some shares remain subject to an underwriter lock‑up tied to the issuer’s convertible senior notes due 2031 (footnote F1).
Shares owned after the transactions: not specified in the excerpt provided.
Filing timing: Form 4 was filed on 2026-03-24 covering trades on Mar 20 and Mar 23; no late filing flag indicated in the provided info.

Context

The 3,708‑share sale is described in the filing as a mandatory sell‑to‑cover for tax withholding tied to RSU vesting (per company RSU Settlement Policy) — such sales are routine and not necessarily a signal of executive sentiment.
The option grant vests monthly over four years; the RSU grant vests quarterly over four years — these are long‑term compensation awards.
Derivative activity (exercise/conversion) is reported separately; when acquisition and disposition of the same number of shares are reported on the same date, it typically reflects conversion/exercise and an accompanying transfer or disposition, but the filing here provides no price detail for that leg.

Form 4

Period: 2026-03-20

Chief Financial Officer

Transactions

Exercise/Conversion
Common Shares
[F1][F2]
2026-03-20+6,250→ 19,273 total
Sale
Common Shares
[F3]
2026-03-23$46.78/sh−3,708$173,460→ 15,565 total
Award
Stock Option (Right to Buy)
[F1][F4]
2026-03-20+38,499→ 38,499 total
Exercise: $46.24Exp: 2036-03-20→ Common Shares (38,499 underlying)
Award
Restricted Stock Units
[F2][F1][F5]
2026-03-20+27,500→ 27,500 total
→ Common Shares (27,500 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F1][F6]
2026-03-20−6,250→ 12,500 total
→ Common Shares (6,250 underlying)

Footnotes (6)

[F1]These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.
[F2]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
[F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
[F4]This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.
[F5]This restricted stock unit award was granted on March 20, 2026 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.
[F6]This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Signature

Elizabeth Ryland Waldinger, attorney-in-fact|2026-03-24

1 file